Boundless Bio, Inc.
A complete Wall Street Score is unavailable because required model components are missing. Missing model components: revenue, financial, Buffett-style model component. These are scoring components, not a claim that the company has no assets or earnings. Missing inputs are not zero and do not by themselves make this a weak company. Available financial statements and source-backed research remain visible.
BOLD · Price history
Price at last available close
$2.41
−$0.20 (-7.66%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Boundless Bio, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers.
How they make money
Boundless Bio is a clinical-stage oncology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future collaborations to fund the research and development of its proprietary ecDNA-directed therapies (ecDTx) for oncogene-amplified cancers.
Products & services
The company is developing a pipeline of ecDNA-directed therapies, including BBI-355, BBI-825, and BBI-940, which are designed to target the unique vulnerabilities of cancer cells driven by extrachromosomal DNA.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Oncology patients with oncogene-amplified tumorsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for clinical trial management, data collection, and the manufacturing of drug candidates for preclinical and clinical studies.Source
Competitors
- Biopharmaceutical and biotechnology companies — The company competes with various entities developing oncology therapeutics, including those focused on precision medicine, targeted therapies, and gene editing technologies.Source
Strengths
- Proprietary Spy platform for identifying and targeting ecDNA-driven cancer vulnerabilitiesSource
Sources
Company-specific research
Questions worth answering for BOLD
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can BOLD fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is BOLD's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for BOLD to reach sustainable profitability?
- •What future growth or profitability would be needed to justify BOLD's current valuation?
- •What does the current corporate distress warning mean for the reliability or interpretation of BOLD's score?
Essential Investment Snapshot
Market Cap
$54.8M
P/E Ratio
-0.9
EPS
$-2.86
52-Week High
$3.16
52-Week Low
$0.96
Beta
0.38
Shares Outstanding
22.4M
Total Debt
$49.0M
Dividend
No current dividend
Liquidation Value / Share
$2.95
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for BOLD
Detected from reported data — verify before acting.MAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingCommunity Sentiment
0 active · 0 total callsNo personal call yet on BOLD.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary Spy platform for identifying and targeting ecDNA-driven cancer vulnerabilities.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of future losses.
- −Dependence on the success of clinical-stage product candidates.
- −A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$2.41
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $901K | $1.3M | $1.1M | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | -$901K | -$1.3M | -$1.1M | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $44.5M | $44.8M | $55.3M | $42.6M | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $23.8M | $18.7M | $18.0M | $12.2M | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $67.1M | $62.3M | $72.2M | $54.8M | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$58.6M | -$56.9M | -$64.3M | -$48.5M | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$68.0M | -$63.6M | -$73.3M | -$54.8M | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$64.0M | -$58.2M | -$65.4M | -$49.4M | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$64.0M | -$58.2M | -$65.4M | -$49.4M | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-2.86 | $-2.60 | $-3.85 | $-2.22 | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 22.45M | 22.36M | 16.98M | 22.24M | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 22.45M | 22.36M | 16.98M | 22.24M | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$1.06
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-100.0%
Cash Change
+37.5%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS increased 51.4%. Cash increased 37.5%. Total debt declined 100.0%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency
Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer
Rumor Mill · BOLD
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial